Want to see TSE:VM full AI Analyst Report?
VM Stock Chart & Stats
C$0.17
>-C$0.01(-5.56%)
At close: 4:00 PM EST
C$0.17
>-C$0.01(-5.56%)
Day’s Range― - ―
52-Week RangeC$0.07 - C$0.22
Previous CloseN/A
Volume12.11K
Average Volume (3M)72.03K
Market Cap
C$25.13M
Enterprise ValueC$17.01M
Total Cash (Recent Filing)C$75.71K
Total Debt (Recent Filing)C$40.00K
Price to Earnings (P/E)―
Beta-0.47
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding179,475,860
10 Day Avg. Volume61,621
30 Day Avg. Volume72,034
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)21.82
Price to Sales (P/S)2339.21
P/FCF Ratio-9.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained triple-digit TTM revenue growth signals genuine early commercialization and product traction in target markets. Over 2-6 months this trend supports scale-up potential: higher volumes can drive fixed-cost absorption, enable margin improvement, and validate demand for both medical and industrial barite products.
Low Leverage / Conservative DebtA lightly levered balance sheet reduces solvency and interest-rate risk, giving the company operational flexibility while it scales. This durable structural advantage lowers near-term bankruptcy risk, makes future financing less constrained, and preserves capacity to invest in processing qualifications or commercial partnerships.
Value‑add Business Model In Medical & Industrial BariteHaving defined pathways—upgrading raw barite to pharmaceutical-grade barium sulfate, selling industrial grades, and pursuing partnerships—creates multiple durable revenue levers. Control over processing and potential regulatory qualification can sustain premium pricing and long-term market access in imaging and industrial applications.
Bears Say
Deep Negative MarginsPersistently negative gross margins and large operating losses indicate unit economics are currently unfavorable. Unless production efficiency or pricing improves, these structural margin deficits will continue to destroy value, impede reinvestment in quality control and regulatory work, and delay a path to sustainable profitability.
Weak Cash Generation / Cash BurnMeaningful negative operating and free cash flows imply the company depends on external financing to fund operations and growth. This durable weakness constrains capital allocation, increases dilution risk from future raises, and limits ability to scale processing capacity or pursue costly pharmaceutical qualification programs without outside funding.
Equity Decline & Negative Returns; Small Scale Vs CostsDeclining equity and negative ROE reflect capital erosion from ongoing losses. The business remains small relative to its fixed and operating cost base, meaning it must materially scale volumes or raise margins to achieve break-even. This structural scale deficit raises long-term execution and financing risk.
Voyageur Pharmaceuticals News
VM FAQ
What was Voyageur Pharmaceuticals’s price range in the past 12 months?
Voyageur Pharmaceuticals lowest stock price was C$0.07 and its highest was C$0.21 in the past 12 months.
What is Voyageur Pharmaceuticals’s market cap?
Voyageur Pharmaceuticals’s market cap is C$25.13M.
When is Voyageur Pharmaceuticals’s upcoming earnings report date?
Voyageur Pharmaceuticals’s upcoming earnings report date is Aug 03, 2026 which is in 12 days.
How were Voyageur Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Voyageur Pharmaceuticals overvalued?
According to Wall Street analysts Voyageur Pharmaceuticals’s price is currently Overvalued.
Does Voyageur Pharmaceuticals pay dividends?
Voyageur Pharmaceuticals does not currently pay dividends.
What is Voyageur Pharmaceuticals’s EPS estimate?
Voyageur Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Voyageur Pharmaceuticals have?
Voyageur Pharmaceuticals has 179,475,860 shares outstanding.
What happened to Voyageur Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Voyageur Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:VM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. specializes in the creation of mineral-based active pharmaceutical ingredients (APIs). The company aims to produce radiocontrast agents utilizing barium and iodine, along with pharmaceutical products derived from bromine. It possesses complete ownership of three barium sulfate deposits in British Columbia, Canada, two of which are of a quality appropriate for the pharmaceutical barite sector. Furthermore, Voyageur holds stakes in a valuable brine project in Utah, United States, known for its high concentrations of iodine, lithium, and bromine. The company transitioned from its previous name, Voyageur Minerals Ltd., to Voyageur Pharmaceuticals Ltd. in December 2019. Its corporate headquarters are located in Calgary, Canada.